



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 24 August 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**

Important notices

- NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding ([NOT-OD-15-137](#)) Office of AIDS Research
- Findings of Research Misconduct ([NOT-OD-15-141](#)); ([NOT-OD-15-142](#))
- Reminder of Legal Requirements Regarding the Acquisition and Use of Human Fetal Tissue for Research Purposes ([NOT-OD-15-143](#))
- Notice of Correction in FOA Description for PA-15-295 "Screening and Brief Alcohol Interventions in Underage and Young Adult Populations" ([NOT-AA-15-013](#))(R01); ([NOT-AA-15-014](#))(R03); ([NOT-AA-15-015](#))(R21).
- Notice of Intent to Publish a Funding Opportunity Announcement for NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) ([NOT-CA-15-023](#)) National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Enabling Biomimetic Tissue-Engineered Technologies for Integrative Cancer Research (U01) ([NOT-CA-15-026](#)) National Cancer Institute
- Notice of Technical Assistance Webinar for RFA-MD-15-014 "NIMHD Transdisciplinary Collaborative Centers for Health Disparities Research on Chronic Disease Prevention (U54)" ([NOT-MD-15-017](#))
- Notice of Change to Eligible Individuals for PAR-15-03 "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)" ([NOT-CA-15-027](#))
- Correction of Due Dates for Letters of Intent for PAR-15-307 "Translational Research on Adducts in Cancer Risk Identification and Prevention U01" ([NOT-CA-15-029](#)); R01 ([NOT-CA-15-030](#)) and R21 ([NOT-CA-15-031](#)) National Cancer Institute
- FDA Requires Mandatory Use of the Federal Financial Report (FFR) System in the eRA Commons beginning November 1, 2015 ([NOT-FD-15-001](#))
- NICHD Launches New Data Sharing Resource to Accelerate Scientific Findings, Improve Health ([NOT-HD-15-028](#)) Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of Change to Funding Opportunity Description of RFA-HL-16-010 "Sickle Cell Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U01)" ([NOT-HL-15-270](#))
- Notice of Availability of Frequently Asked Questions and Webinar for RFA-HL-16-010 "Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U01)" ([NOT-HL-15-271](#))
- Change in Budget Limit Change for AHRQ General Research (R01) and Research Demonstration (R18) Grant Applications ([NOT-HS-15-013](#))
- Notice of Expiration of PAR-15-022 "Brain Somatic Mosaicism and its Role in Psychiatric Disorders (Collaborative U01)" ([NOT-MH-15-026](#)) National Institute of Mental Health
- Notice of Expiration of PAR-14-173 " Brain Somatic Mosaicism and its Role in Psychiatric Disorders (U01)" ([NOT-MH-15-027](#)) National Institute of Mental Health

1. Title: Short-term Measurements of Improved Physical and Molecular Resilience in Pre-clinical Models**Letter of Intent due date:** Usually 30 days prior to application due date **Hyperlink:** [\(RFA-AG-16-006\)](#) **Type:** RO1**Application Due Date:** November 4, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Therefore submission of SU applications will be 2 days before the application due date above.**Purpose:** This Funding Opportunity Announcement (FOA) invites applications to develop short-term surrogate tests that provide a comprehensive measure of resilience in animal models of aging. Applicants may also include aims to assess resilience in humans to identical or analogous stressors to those proposed for their animal model studies. Resilience is defined here as the ability of an organism to adequately respond to physical or molecular challenges or stresses. Greater resilience has been hypothesized to correlate with longevity and better healthspan, but appropriate methodology to test this in animal models is currently lacking. The purpose of this FOA is to develop tests that can be used to measure resilience to physical or molecular stresses, but does not include psychological or social stressors. The outcomes should lead to short-term tests of resilience that are predictive of subsequent health. In the context of animal studies, this predictability should be tested against manipulations known to increase lifespan and healthspan.**Budget:** Application budgets need to reflect the actual needs of the proposed project but direct costs should be limited to a maximum of \$250,000 per year. The maximum project period is 5 years.**2. Title: Oral HIVacc: Oral Mucosal Immunization Approaches for HIV Prevention****Letter of Intent due date:** Usually 30 days prior to application due date **Hyperlink:** [\(RFA-DE-16-006\)](#) **Type:** RO1**Application Due Date:** November 24, 2015 and November 23, 2016, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Therefore submission of SU applications will be 2 days before the application due date above.**Purpose:** This Funding Opportunity Announcement (FOA) solicits research projects to develop and test novel HIV vaccines for direct administration into oral lymphoid tissues to trigger protective, local and systemic immunity. Specifically, this FOA seeks research projects to: 1) define the mechanisms by which direct HIV vaccination of oral lymphoid tissues induce oral innate as well as local and systemic adaptive immune responses; 2) determine the mechanisms by which new adjuvants used together with oral HIV vaccine candidates enhance local and systemic immunity; 3) test innovative, oral vaccine vectors expressing HIV vaccine antigens to trigger protective immunity; 4) compare different HIV vaccine immunization strategies and schemes for the oral mucosa to maximize protection; and 5) delineate the role of dynamic changes in oral and immune cell subsets and their interactions to enhance immunity upon oral HIV vaccination.**Budget: RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.**3. Title: Ethical, Legal and Policy Issues in HIV Research with Key Populations****Letter of Intent due date:** Usually 30 days prior to application due date **Hyperlink:** [\(PAR-15-328\)](#) **Type:** RO1[\(PAR-15-327\)](#) R21**Application Due Date:** January 7, 2016; September 7, 2016; January 7, 2017; September 7, 2017; January 8, 2018; September 7, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Therefore submission of SU applications will be 2 days before the application due date above.**Purpose:** This Funding Opportunity Announcement (FOA) encourages applications to analyze and address ethical, legal, or policy challenges specific to work with key populations in HIV research or health care. Proposed projects should be focused on ethical, legal or policy challenges in relation to research studies or program implementation for HIV or associated co-morbidities, affecting one or more of the following key populations: (1) men who have sex with men; (2) people who inject drugs; (3) people in prisons and other closed settings; (4) sex workers; (5) transgender people or (6) adolescent girls and young women at high risk of HIV acquisition or who are living with HIV. This FOA encourages both empirical and conceptual research projects addressing these topics.**Budget: RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.**4. Title: Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD)****Letter of Intent due date:** Usually 30 days prior to application due date **Hyperlink:** [\(PAR-15-330\)](#) **Type:** U19**Application Due Date:** March 9, 2016; March 9, 2017; March 9, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Therefore submission of SU applications will be 2 days before the application due date above.**Purpose:** The goal of the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) Funding Opportunity Announcement (FOA) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials. A preclinical research application alone is not sufficient for this announcement. Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the project period of the award. However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. Investigators are expected to begin clinical studies by the end of the award.**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. As a guideline, the approximate range of funding in direct costs is expected to be \$1.5 to \$2.5 million per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Title: Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD)**Letter of Intent due date:** Usually 30 days prior to application due date **Hyperlink:** [\(PAR-15-330\)](#) **Type:** U19**Application Due Date:** March 9, 2016; March 9, 2017; March 9, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Submission of SU applications will be 2 days before the application due date above.**Purpose:** The goal of the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) Funding Opportunity Announcement (FOA) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials. A preclinical research application alone is not sufficient for this announcement. Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the project period of the award. However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. Investigators are expected to begin clinical studies by the end of the award.**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. As a guideline, the approximate range of funding in direct costs is expected to be \$1.5 to \$2.5 million per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.**6. Title: NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders****Letter of Intent due date:** Usually 30 days prior to application due date **Hyperlink:** [\(RFA-DA-16-008\)](#) **Type:** UG3/UH3**Application Due Date:** December 3, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Submission of SU applications will be 2 days before the application due date above.**Purpose:** The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.**Budget:** Application budgets are limited to \$1,000,000 direct costs per year and need to reflect the actual needs of the proposed project. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.**7. Title: NEI Audacious Goal Initiative: Discovery-based Science to Identify factors Influencing Neural Regeneration in the Visual System****Letter of Intent due date:** Usually 30 days prior to application due date **Hyperlink:** [\(RFA-EY-15-002\)](#) **Type:** UO1**Application Due Date:** January 15, 2016, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Submission of SU applications will be 2 days before the application due date above.**Purpose:** The NEI Audacious Goal Initiative (AGI; see <https://www.nei.nih.gov/audacious>) is to restore vision through regeneration of neurons and neural connections in the eye and visual system. Recent advances have identified molecules and signaling pathways that can either promote or inhibit regeneration of neurons in the visual pathway. These advances have led to significant axon growth in mouse optic-nerve crush and other regeneration models. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing to use discovery-based approaches to identify unknown factors critical to the regeneration of neurons, guiding their axons to targets, and making new functional connections. Future FOAs will focus on understanding the biological mechanisms through which these factors influence regeneration.**Budget:** Application budgets are limited to \$500,000 annual direct costs (including the direct costs of any subcontracts proposed), and must reflect the actual needs of the proposed project. The project period is limited to three years.**8. Title: Chemistry, Toxicology, and Addiction Research on Waterpipe Tobacco****Letter of Intent due date:** Usually 30 days prior to application due date, but for this FOA, letters are requested on October 13, 2015. **Hyperlink:** [\(RFA-OD-15-005\)](#) **Type:** RO1**Application Due Date:** November 20, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Submission of SU applications will be 2 days before the application due date above.**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral, and social science research that will inform the development and evaluation of possible regulatory action on waterpipe (or hookah) tobacco products. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by the National Institutes of Health (NIH) using designated funds from the FDA CTP for tobacco regulatory science. Research results from this FOA are expected to generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of waterpipes to protect public health.**Budget:** Application budgets are not to exceed \$300,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

9. Title: Early-Stage Development of Informatics Technologies for Cancer Research and Management

Letter of Intent due date: Usually 30 days prior to application due date **Hyperlink:** [\(PAR-15-332\)](#) **Type:** U01

Application Due Date: November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Submission of SU applications will be 2 days before the application due date above.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included.

Budget: Budgets are limited to \$300,000 Direct Costs (excluding consortium F&A costs) per year. The maximum project period is three years.

10. Title: Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management

Letter of Intent due date: Usually 30 days prior to application due date **Hyperlink:** [\(PAR-15-334\)](#) **Type:** R21

Application Due Date: November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Submission of SU applications will be 2 days before the application due date above.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant (R21) applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed informatics method or algorithm must have a clear rationale on why it is novel and how it will benefit the cancer research field. Potential applicants who are interested in more downstream tool development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.

Budget: Direct costs are limited to \$275,000 over a two year period. No more than \$200,000 may be requested in any single year. The maximum project period is two years.

11. Title: Exploratory Multi-site Palliative Care Research in Diverse Populations Utilizing the Palliative Care Research Cooperative (PCRC) Group

Letter of Intent due date: Usually 30 days prior to application due date **Hyperlink:** [\(PAR-15-337\)](#) **Type:** R21

Application Due Date: November 30, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Submission of SU applications will be 2 days before the application due date above.

Purpose: The purpose of this initiative is to stimulate research that enhances the knowledge-base of palliative care science across diverse populations receiving end-of-life and palliative care (EOLPC) through multi-site clinical research that utilizes the infrastructure and resources of the Palliative Care Research Cooperative (PCRC) Group. The aim of this Funding Opportunity Announcement is to increase the knowledge of EOLPC science across diverse populations; add to the common data core regarding EOLPC; and build collaborative, interdisciplinary science.

Budget: The combined budget for direct costs, excluding consortia F&A, for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. The maximum project period is 2 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

Complete [Glossary and acronym list of NIH Terms](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: **Dr Christa Coetsee** • Tel: 9838 • Email: cdevries@sun.ac.za